COO — The Cooper Companies, Inc.

The September 9, 2026 Q3 FY26 report cut FY26 revenue guidance to $4.23-4.25B and non-GAAP EPS to $4.51-4.55 on US CooperVision channel destocking, and the board simultaneously concluded its strategic review by deciding NOT to sell CooperSurgical - killing the separation thesis that had supported the multiple. The stock fell ~15% in one session; Baird (Outperform->Neutral, PT $85->$61), BofA (Buy->Neutral, PT $80->$65) and Needham (Buy, PT $86->$73) all cut targets, and the consensus rating slid to Hold. As of 2026-09-13, the 1-week return was -22.5%, 1-month -29.7%, 3-month -20.6% and 6-month -22.9% - this is capitulation pricing, even though management described underlying end-user demand as stable.

Revenue has grown from $927.1M in Q4 FY23 (Oct-2023) to $1,066.2M in Q3 FY26 (Jul-2026), but the growth rate is clearly decelerating: Q4 FY25 +4.6% YoY, Q1 FY26 +6.2%, Q2 FY26 +7.9%, then Q3 FY26 +0.6% - a sharp stall. Reported profitability is badly distorted by two one-offs: Q2 FY26 posted an operating loss of -$31.0M (versus ~$185M in adjacent quarters, consistent with an impairment/goodwill charge) and a -$0.40 GAAP EPS, while Q3 FY26's GAAP EPS of $2.24 includes a $307.2M discrete UK tax benefit (non-GAAP EPS was $1.15 vs $1.12 expected). Strip those out and the underlying picture is: gross margin compressed to 62.4% in Q3 FY26 from 65.3% a year earlier, operating margin of 20.9% in Q3 FY26 (vs 16.6% in Q3 FY25) looks like expansion but is flattered by the low Q2 base, and TTM operating margin sits at 12.9% with ROIC at 4.0% - both depressed by the Q2 charge. TTM free cash flow is a solid ~$552M (Q3 FY26 alone $146.8M on FMP's definition; the company cited a record $273M on its own definition). My read: the Q2 charge is a one-off, the Q3 revenue stall is a self-imposed channel-inventory reset rather than demand destruction, but the burden of proof is now on management - a second consecutive deceleration would turn 'blip' into 'trend.'

Cheap, with a value-trap caveat. As of 2026-09-13: TTM P/E 18.4 vs a 5-year average of 36.9x; P/S 2.48 vs a 5-year average of 4.85x; P/B 1.25; PEG 0.42; EV/EBITDA 14.08 (about 11.4x if you add back the Q2 FY26 impairment to normalized EBITDA of roughly $1.09B). On the FY2027 consensus EPS of $4.543 the stock trades at ~11.9x forward - a multiple you'd normally associate with a no-growth or structurally challenged asset, not a 63%-gross-margin consumable medtech franchise with ~95%+ contact-lens retention. The catch: the 5-year average P/E of 36.9x was earned in a higher-growth era, so some of the derating is deserved; the guidance cut and the dead CooperSurgical sale are real, and forward estimates may still be stale post-September 9.

The market is now pricing a stalled business: ~11.9x forward non-GAAP EPS of $4.543 versus a 5-year average P/E near 37x. Two readings are possible. Bear case: revenue growth of +0.6% YoY is the new run-rate, destocking is a symptom of distributors leaning out working capital permanently, and 11.9x can get cheaper. Bull case: the stall is a temporary channel reset at CooperVision (US only) with end demand stable, FY2027 consensus of $4.543 is only ~flat versus the current FY26 guide midpoint of $4.53, and a $3B buyback at ~$54 could retire ~5% of shares annually, mechanically lifting EPS even on flat net income. The tell is the December 2026 Q4 print: if CooperVision US revenue reaccelerates and FY2027 guidance comes in at or above $4.60, the current multiple is mispricing a consumable franchise; if Q4 destocking drags and the FY27 guide is cut again, the 52-week low of $51.01 is not a floor.

As of 2026-09-13, RSI(14) stood at 14.52 - extraordinarily oversold (below 20 is rare) - with price 23.4% below the 20-day SMA, 24.8% below the 50-day and 26.3% below the 200-day, and a 1-week return of -22.5%. This is a capitulation/re-rating event, not a normal pullback, and short-term oversold readings of this depth usually precede a reflex bounce rather than more downside. That said, 'oversold' is not a buy signal on its own - a stock can stay pinned near RSI 20 for weeks while the fundamental headline (December Q4 earnings) resolves. Practical read: do not chase into the print; wait for stabilization (RSI reclaiming 30, price closing back above the 20-day SMA, or a higher low above the $51.01 52-week low) before treating the drawdown as an entry.

• US medtech channel inventory normalization - distributors and channel partners are leaning out working capital, which is the direct cause of COO's CooperVision destocking; end-user lens demand is reportedly stable, but the timing of the reset is management-controlled and hard to model.
• Higher-for-longer interest rates - COO's leverage is modest (debt/equity 0.305, long-term debt/equity 0.23) and ~$552M TTM free cash flow means the expanded $3B buyback can be self-funded without capital markets dependence, which is a genuine relative advantage.
• Medtech multiple compression / sector rotation out of premium-priced healthcare - COO's derating from ~37x to ~12x forward is partly idiosyncratic, but partly a sector-wide de-rating of high-multiple device names.
• Fertility and elective procedure demand in CooperSurgical (fertility +5% organic) - sensitive to consumer discretionary budgets and reimbursement policy, but currently a rare bright spot.
• FX and international exposure - revenue spans 130+ countries, so a softer dollar is a tailwind; the $307.2M UK tax benefit also shows the tax line can swing results materially in either direction.

• Q4 and full-year FY2026 earnings, expected early December 2026 - the single most important datapoint: does CooperVision US channel destocking end, and what does FY2027 guidance look like versus the $4.543 consensus?
• Execution pace on the expanded $3B share repurchase authorization (raised from $2B) - at ~$54/share, full deployment would retire a very large share of the ~195M shares outstanding and would mechanically lift EPS even with flat net income.
• A re-opening of strategic alternatives for CooperSurgical (spin-off, IPO, or sale) - the board said retention creates more value, but the segment's ~2% growth and +5% organic fertility performance could revive the separation case.
• Product mix and new launches in specialty lenses (toric, multifocal, myopia management) and continued CooperSurgical fertility strength.
• Any stabilization or reversal in the tightly clustered analyst target range ($59 low, $65.75 consensus, $66.43 recent average, $75 high) as estimates are refreshed post-guidance cut.

• Destocking extends beyond Q4 FY26 into FY2027, converting what management calls a temporary channel reset into a persistent revenue drag, and forcing another guidance cut.
• The CooperSurgical retention decision removes the cleanest value-unlock catalyst and represents a credibility hit - the review ran for months and ended with no action plus a guide-down in the same release.
• GAAP versus non-GAAP divergence is large and persistent: TTM GAAP EPS of $2.949 versus ~$4.53 guided non-GAAP, implying heavy acquired-intangible amortization and leaving room for further impairments that flatter cash flow but hit reported earnings.
• Competitive intensity in soft contact lenses (Alcon, J&J Vision, Bausch + Lomb) and in myopia management, where pricing and share could erode if Cooper's channel reset signals weakness to rivals.
• Liquidity is adequate but not generous: current ratio 1.222 and quick ratio 0.734, with only $154.7M of cash against $1.92B of long-term debt - the strong FCF covers it, but there is limited balance-sheet cushion if the downturn in volumes persists.

COO is a genuinely good consumables franchise - 63% gross margin, recurring contact-lens revenue with high retention, ~$552M of TTM free cash flow, low leverage - that has been hit by a self-inflicted channel-inventory reset, a failed separation process, and a credibility-damaging guidance cut all in one quarter, and it now trades at ~11.9x forward earnings against a 5-year average near 37x. The risk/reward has shifted from unfavorable to roughly balanced-to-attractive, but this is not a clean 'buy the dip': the December Q4 print is binary, and until destocking is proven finished a value trap is a real possibility. I would treat it as a name to build on evidence (Q4 stabilization or a higher low) rather than into the current capitulation print. This is analysis, not personalized financial advice.

I applied a 15x forward P/E to FY2027 consensus EPS of $4.543, giving $68.15 - a deliberate discount to COO's 5-year average P/E of ~37x (a premium earned during a higher-growth era) and a premium to the ~11.9x it trades at as of 2026-09-13, justified by 63% gross margins, consumable/recurring contact-lens revenue, ~$552M TTM free cash flow and an expanded $3B buyback that can retire roughly 5% of shares annually. Cross-check: 12.5x EV/EBITDA on normalized EBITDA of ~$1.09B (adding back the ~$215M Q2 FY26 impairment to the implied ~$872M TTM figure) yields roughly $61, so the two methods bracket $61-68 and I anchor at $68, modestly above the $65.75 analyst consensus and inside the $59-75 target range. This is my own calculation, not a restatement of either the analyst target or the deterministic value score's band.